

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

NCT06729996

Status	RECRUITING
Phase	Phase 2
Sponsor	Mayo Clinic
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (8)

- Age e18-80 years at the time of enrollment.
- RAP or CP with DM diagnosed before or after CP diagnosis (Confirmed CP on imaging or RAP based on PROCEED study criteria, and confirmed DM as per ADA criteria or clinically diagnosed with DM and on antihyperglycemic therapy)
- Able to provide written informed consent and participate in longitudinal follow-up
- A Stable retinal exam within 1 year prior to enrollment unless new onset diabetes was diagnosed within 6 months prior to study enrollment. If an eye exam within the past year is not available but the most recent exam is stable, a standard of care eye exam needs to be scheduled during the study period.
- HbA1c level 6.5-10.5% at screening visit.

... and 3 more (see full listing online)

Exclusion (17)

- Inability to take PIO or EMPA due to prior hypersensitivity or allergic reaction or current use of medications with potential for drug-drug interactions (Pioglitazone: Drug information - UpToDate, Empagliflozin: Drug information - UpToDate)
- Patients on PIO or EMPA at the time of screening
- Diagnosed with Type 1 Diabetes
- Pregnancy or lactation in women (positive urine pregnancy test at screening will lead to exclusion)
- History of bleeding disorders (e.g., Hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), von Willebrand disease, platelet disorders etc)

... and 12 more (see full listing online)

Locations (2 total)

Mayo Clinic, Rochester, Minnesota, United States

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States